Bariatric surgery in HIV-infected patients: review of literature

Erika Ferrari Rafael da Silva


Obesity is now a common problem among HIV-infected patients receiving antiretroviral therapy
(ART). Until recently, HIV infection has been considered a contraindication to bariatric surgery for
various reasons. Insurance carriers have considered HIV a terminal disease, and surgeons have been
reluctant to operate HIV-infected patients because of this, as well as the associated risk of infectious
transmissions, although this has been changing. Gastric bypass surgery may be an option for some
patients who have failed diet and therapeutic lifestyle changes, modification in ART or other treatment
modalities for HIV/ART-related lipohypertrophy and obesity. However, few data are available regarding
HIV-related outcomes after such surgery and its impact on ART tolerability. The aim of this study is to
review bariatric surgery in HIV-infected patients.


HIV, obesity, bariatric surgery

Full Text:



UNAIDS report on the global AIDS epidemic 2016. [cited

July 2016]; Available from:


Boletim Epidemiológico HIV/aids. Ministério da Saúde,

Distrito Federal 2015. Ano IV número 01.

Hogg RS, Heath KV, Yip B, et al. Improved survival among

HIV-infected individuals following initiation of antiretroviral

therapy. JAMA 1998; 279:450-4.

Palella, FJ Jr, Delaney, KM, Moorman, AC, et al. Declining

morbidity and mortality among patients with advanced

human immunodeficiency virus infection. N Engl J Med

; 338:853– 60.

Enanoria WTA, Ng C, Saha SR, et al. Treatment outcomes

after highly active antiretroviral therapy: A meta-

-analysis of randomized controlled trials. Lancet Infect Dis

; 4:414 -25.

Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in

the highly active antiretroviral therapy era: changing causes

of death and disease in the HIV outpatient study. J

Acquir Immune Defic Syndr 2006; 43:27–34.

Weber R, Ruppik M, Rickenbach M, et al. Decreasing

mortality and changing patterns of causes of death in the

Swiss HIV Cohort Study. HIV Med 2013; 14:195–207.

Carr A, Samaras K, Burton S, et al. A syndrome of peripheral

lipodystrophy, hyperlipidaemia and insulin resistance

in patients receiving HIV protease inhibitors. AIDS

; 12:F51– 8.

Walli R, Herfort O, Michl GM, et al. Treatment with protease

inhibitors associated with peripheral insulin resistance

and impaired glucose tolerance in HIV-1–infected

patients. AIDS 1998; 12:F167–74.

Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction,

and natural course of HIV protease inhibitor–associated

lipodystrophy, hyperlipidaemia, and diabetes mellitus.

Lancet 1999; 353:2893–9.

Saint-Marc T, Partisani M, Poizor-Martin I, et al. A syndrome

of peripheral fat wasting (lipodystrophy) in patients

receiving long-term nucleoside analogue therapy. AIDS

; 13:1359–67.

Henry K, Melroe H, Huebsch J, et al. Severe premature

coronary artery disease with protease inhibitors. Lancet

; 351(9112):1328.

Flynn TE, Briscker LA. Myocardial infarction in HIV-infected

men receiving protease inhibitors. Ann Intern Med

; 131:258.

Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery

and cardiovascular risk factors: a scientific statement

from the American Heart Association. Circulation 2011;


Global Health Observatory (GHO): Obesity. World Health

Organisation, editor. 7-4-2014. Available at: http://www. factors/bmi_text/en/. Accessed January

, 2015.

Sturm R. Increases in morbid obesity in the USA: 2000-

Public Health 2007; 121:492-6.

Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP.

Visceral obesity: the link among inflammation, hypertension,

and cardiovascular disease. Hypertension 2009;


Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular

disease: pathophysiology, evaluation, and effect of

weight loss: an update of the 1997 American Heart Association

Scientific Statement on Obesity and Heart Disease

from the Obesity Committee of the Council on Nutrition,

Physical Activity, and Metabolism. Circulation 2006;113:


Tang, AM., Jacobson, DL., Spiegelman, D., Knox, TA., &

Wanke, C. Increasing risk of 5% or greater unintentional

weight loss in a cohort of HIV-infected patients, 1995 to

J Acquir Immune Defic Syndr 2005; 40, 70-76.

Carr, A., Samaras, K., Burton, S., Law, M., Freund, J.,

Chisholhm, D., et al. A syndrome of peripheral lipodystrophy,

hyperlipidemia and insulin resistance in patients receiving

HIV protease inhibitors. AIDS 1998; 14, F25-F32.

Heath, K. V., Hogg, R. S., Singer, J., Chan, K. J.,

O’Shaughnessy, M. W., & Montaner, J. S. Antiretroviral

treatment patterns and incident HIV-associated morphologic

and lipid abnormalities in a population-based cohort.

J Acquir Immune Defic Syndr 2002; 30: 440-447.

Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M.

A., Tabak, C. J., & Flegal, K. M. Prevalence of overweight

and obesity in the United States, 1999-2004. J Am Med

Assoc, 2006; 295: 1549-1555.

Grundy, S. M., Brewer, H. B., Jr., Cleeman, J. I., Smith,

S. C., Jr., & Lenfant, C. Definition of metabolic syndrome:

Report of the National Heart, Lung, and Blood Institute/

American Heart Association Conference on Scientific Issues

Related to Definition. Circulation 2004; 109: 433-

Thompson-Paul AM1, Wei SC, Mattson CL, Robertson

M, Hernandez-Romieu AC, Bell TK et al. Obesity Among

HIV-Infected Adults Receiving Medical Care in the United

States: Data From the Cross-Sectional Medical Monitoring

Project and National Health and Nutrition Examination

Survey. Medicine (Baltimore) 2015; 94(27):1-10.

Keithley JK, Duloy AM, Swanson B, et al. HIV infection

and obesity: a review of the evidence. J Assoc Nurses in

AIDS Care: JANAC 2009; 20(4):260–74.

Hsue P, Hunt P, Schnell A, et al. Role of viral replication,

antiretroviral therapy, and immunodeficiency in HIVassociated

atherosclerosis. AIDS 2009; 23:1059–1067.

Boccara F. Cardiovascular complications and atherosclerotic

manifestations in the HIV-infected population: Type,

incidence and associated risk factors. AIDS 2008; 22 (Suppl

: S19–S26.

Miller M, Kahraman A, Ross B, et al. Evaluation of quantitative

liver function tests in HIV-positive patients under anti-

retroviral therapy. Eur J Med Res 2009; 14(9):369–77.

Adams TD, Gress RE, Smith SC, et al. Long-term mortality

after gastric bypass surgery. N Engl J Med 2007;


Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories

W, Fahrbach K et al. Bariatric surgery: a systematic review

and meta analysis. JAMA 2004; 292(14):1724–37.

Sjostrom L, Lindross A, Peltonen, et al. Lifestyle, diabetes,

and cardiovascular risk factors 10 years after bariatric

surgery. N Engl J Med 2004; 351:2683–2693.

Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric

surgery on mortality in Swedish obese subjects. N Engl J

Med 2007; 357:741–752.

Adams T, Gress R, Smith S, et al. Long-term mortality after

gastric bypass surgery. N Engl J Med 2007; 357:753–

The Longitudinal Assessment of Bariatric Surgery (LABS)

Consortium. Perioperative Safety in the Longitudinal

Assessment of Bariatric Surgery. N Engl J Med 2009;


Jensen MD, Ryan DH, Donato KA, et al. Executive summary:

guidelines (2013) for the management of overweight

and obesity in adults: a report of the American College

of Cardiology/American Heart Association Task Force on

Practice Guidelines and The Obesity Society Published

by The Obesity Society and American College of Cardiology/

American Heart Association Task Force on Practice

Guidelines. Based on a systematic review from The

Obesity Expert Panel, 2013. Obesity (Silver Spring) 2014;

(suppl 2):S5-39.

Keithley JK, Duloy MAS, Swanson B,Zeller JM. HIV Infection

and Obesity: A Review of the Evidence. Journal of the

Association of Nurses in AIDS Care 2009; 20(4):260-274

American Diabetes Association. Standards of medical

care in diabetes. Diabetes Care 2013; 36:S11-66.

Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery:

an IDF statement for obese type 2 diabetes. Diabet

Med 2011; 28:628-42.

Rubino F, Kaplan LM, Schauer PR, Cummings DE. The

Diabetes Surgery Summit consensus conference: recommendations

for the evaluation and use of gastrointestinal

surgery to treat type 2 diabetes mellitus. Ann Surg 2010;


Brolin RE. Update: NIH consensus conference. Gastrointestinal

surgery for severe obesity. Nutrition 1996; 12:403-4.

Mechanick JI, Youdim A, Jones DB, et al. Clinical practice

guidelines for the perioperative nutritional, metabolic, and

nonsurgical support of the bariatric surgery patiente2013

update: cosponsored by American Association of Clinical

Endocrinologists, the Obesity Society, and American

Society for Metabolic and Bariatric Surgery. Endocr Pract

; 19:337-72.

Flum DR, Belle SH, King WC, et al. Perioperative safety

in the longitudinal assessment of bariatric surgery. N Engl

J Med 2009;361: 445-54.

Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular

evaluation and management of severely obese patients

undergoing surgery: a Science advisory from the American

Heart Association. Circulation 2009;120: 86-95.

Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN.

Obesity and cardiovascular diseases: implications regarding

fitness, fatness, and severity in the obesity paradox.

J Am Coll Cardiol 2014; 63:1345-54.

Fisher BL, Schauer P. Medical and surgical options in the treatment

of severe obesity. Am J Surg 2002;184(6B):9S-16S.

Karmali S, Schauer P, Birch D, Sharma AM, Sherman V.

Laparoscopic sleeve gastrectomy: an innovative new tool

in the battle against the obesity epidemic in Canada. Can

J Surg 2010; 53:126-32.

Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide

Obes Surg 2009; 19:1605-11.

Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi

V. Biliopancreatic bypass for obesity: II. Initial experience

in man. Br J Surg 1979; 66:618-20.

Hess DS, Hess DW. Biliopancreatic diversion with a duodenal

switch. Obes Surg 1998; 8:267-82.

Marceau P, Hould FS, Potvin M, Lebel S, Biron S. Biliopancreatic

diversion (doudenal switch procedure). Eur J

Gastroenterol Hepatol 1999; 11:99-103.

Flancbaum L, Drake V, Colarusso T, et al. Initial experience

with bariatric surgery in asymptomatic human immunodeficiency

virus-infected patients. Surg Obes Relat Dis

: 1:73–76.

Fazylov R, Soto E, Merola S. Laparoscopic gastric by-

-pass surgery in human immunodeficiency virus-infected

patients. Surg Obes Relat Dis 2007; 3:637–639.

Selke H, Norris S, Osterholzer D, Kenneth, Fife KH, De-

Rose B, Gupta SK. AIDS Patient Care and STDs 2010;

(9): 545-550.

Fysekidis M, Cohen R, Bekheit M, Chebib J, Boussairi A,

Bihan H et al.Sleeve gastrectomy is a safe and efficient

procedure in HIV patients with morbid obesity: a case series

with results in weight loss, comorbidity evolution, CD4

count, and viral load. Obes Surg 2015; 25:229–233.

Eddy F, Elvin S, Sanmani L. Bariatric Surgery: An HIV-positive

patient’s successful journey. Int J STD AIDS. 2015


Pourcher G, Costagliola D, Martinez V, Obesity in HIV-infected

patients in France: Prevalence and surgical treatment

options. Journal of Visceral Surgery 2015; 9:633-35.


Zivich S, Cauterucci M, Allen S, Vetter M. Long-term virologic

outcomes following bariatric surgery in patients with

HIV. Obes Res Clin Pract 2015;

Sardo P, Walker JH. Bariatric surgery: impact on medication

management. Hosp Pharm 2008; 43(2):113–20.

Brocks DR, Ben-Eltriki M, Gabr RQ, et al. The effects

of gastric bypass surgery on drug absorption and pharmacokinetics.

Expert Opin Drug Metab Toxicol 2012;


Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics

of levothyroxine in severely obese volunteers.

Thyroid: Off J Am Thyroid Assoc 2011; 21(5):477–81.

Kamimura M, Watanabe K, Kobayakawa M, et al. Successful

absorption of antiretroviral drugs after gastrojejunal

bypass surgery following failure of therapy through a jejunal

tube. Intern Med 2009; 48(12):1103–4.

Boffito M, Lucchini A, Maiello A, et al. Lopinavir/ritonavir Absorption

in gastrectomized patient. AIDS 2003; 17:136-137



  • There are currently no refbacks.